Tillmann Krahnke

2.0k citations

27 papers · 1.5k indexed · 1 hit paper · h-index 13

Hematology top 1%
- Chronic Myeloid Leukemia Treatments 12
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 12
Rheumatology top 1%
- Eosinophilic Disorders and Syndromes 7
Gastroenterology top 5%
Endocrinology, Diabetes and Metabolism top 10%
Pharmacology
- Cholinesterase and Neurodegenerative Diseases 5
Psychiatry and Mental health
- Dementia and Cognitive Impairment Research 4
Physiology
- Alzheimer's disease research and treatments 3
Epidemiology
- Neuroendocrine Tumor Research Advances 2
Infectious Diseases
- COVID-19 Clinical Research Studies 2

Co-authors: Brian Druker François Guilhot Richard A. Larson Stephen G. O’Brien Insa Gathmann Yanfeng Wang Jörge E. Cortes Hagop M. Kantarjian
Cited by: Hematology Genetics Rheumatology
Journals: Journal of Clinical Oncology (1 paper)Blood (9 papers)The Journal of Clinical Endocrinology & Metabolism (1 paper)
Partner nations: United States Switzerland Germany

In The Last Decade

Tillmann Krahnke

27 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Tillmann Krahnke

Since Specialization

Citations

This map shows the geographic impact of Tillmann Krahnke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tillmann Krahnke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tillmann Krahnke more than expected).

Fields of papers citing papers by Tillmann Krahnke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tillmann Krahnke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tillmann Krahnke. The network helps show where Tillmann Krahnke may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tillmann Krahnke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tillmann Krahnke Line = papers co-authored together Tillmann Krahnke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy Participants Advances in Therapy ·Christine Farenc,P Clot,Salvatore Badalamenti,Annie J. Kruger,Robert J. Pomponio,Tillmann Krahnke,Heribert Staudinger,Yong Lin	2025	1
2	Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study Respiratory Research ·P Clot,Christine Farenc,Benjamin T. Suratt,Tillmann Krahnke,Agnes Tardat,Peter Florian,Robert J. Pomponio,Naimish Patel,Maria Wiekowski,Yong Lin,Benjamin Terrier,Heribert Staudinger	2024	12
3	Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19 P Clot,Christine Farenc,Benjamin T. Suratt,Tillmann Krahnke,Agnes Tardat,Peter Florian,Robert J. Pomponio,Naimish Patel,Maria Wiekowski,Yong Lin,Benjamin Terrier,Heribert Staudinger	2021	2
4	MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM) Annals of Oncology ·Marc S. Raab,Roberto Ria,Jana Schlenzka,Tillmann Krahnke,Jutta Haunschild,F. Herrmann,Ulrike Fiedler,Keith M. Dawson,Michael T. Stumpp,Keyvan Tadjalli Mehr,A. Harstrick,Angelo Vacca,H. Goldschmidt	2017	1
5	A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects CPT Pharmacometrics & Systems Pharmacology ·Marc Vandemeulebroecke,Björn Bornkamp,Tillmann Krahnke,Johanna Mielke,Andreas U. Monsch,Peter Quarg	2017	16
6	Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies Alzheimer s Research & Therapy ·Jana Podhorná,Tillmann Krahnke,Michael Shear,John Harrison,(unknown)	2016	63
7	Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch Alzheimer s Research & Therapy ·José Luís Molinuevo,Lutz Frölich,George T. Grossberg,James E. Galvin,Jeffrey L. Cummings,Tillmann Krahnke,Christine Strohmaier	2015	15
8	Predictors of response to the 13.3 and 9.5mg/24h rivastigmine patch: The optimizing /INS;transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study Journal of the Neurological Sciences ·José Luís Molinuevo,George T. Grossberg,Lutz Frölich,James E. Galvin,Tillmann Krahnke,Christine Strohmaier	2013	3
9	High-dose 13.3mg/24h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer's disease with and without concomitant memantine use Journal of the Neurological Sciences ·José Luís Molinuevo,Jeffrey L. Cummings,Lutz Frölich,James E. Galvin,Tillmann Krahnke,Christine Strohmaier	2013	3
10	P3–275: Incidence and predictors of response to the 13.3 (15 cm²) and 9.5 mg/24h (10 cm²) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study Alzheimer s & Dementia ·José Luís Molinuevo,George T. Grossberg,Lutz Frölich,James E. Galvin,Tillmann Krahnke,Christine Strohmaier	2013	5
11	Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease American Journal of Alzheimer s Disease & Other Dementias® ·George T. Grossberg,Jeffrey L. Cummings,Lutz Frölich,Giuseppe Bellelli,José Luís Molinuevo,Tillmann Krahnke,Christine Strohmaier	2013	12
12	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase Cancer ·Hagop M. Kantarjian,Richard A. Larson,François Guilhot,Stephen G. O’Brien,Manisha Mone,Marc S. Rudoltz,Tillmann Krahnke,Jörge E. Cortes,Brian Druker,(unknown)	2009	86
13	Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studybreakdown → Blood ·Richard A. Larson,Brian Druker,François Guilhot,Stephen G. O’Brien,Gilles J. Riviere,Tillmann Krahnke,Insa Gathmann,Yanfeng Wang	2008	491
14	Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias Annals of Oncology ·Renaud Capdeville,Tillmann Krahnke,Alan K. Hatfield,J. Ford,Iris van Hoomissen,Insa Gathmann	2008	12
15	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment Blood ·Andreas Hochhaus,Brian Druker,Charles L. Sawyers,François Guilhot,Charles A. Schiffer,Jörge E. Cortes,Dietger Niederwieser,Carlo Gambacorti‐Passerini,Richard M. Stone,John M. Goldman,Thomas Fischer,Stephen G. O’Brien,J Reiffers,Manisha Mone,Tillmann Krahnke,Moshe Talpaz,Hagop M. Kantarjian	2007	160
16	Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood ·Hagop M. Kantarjian,Brian Druker,François Guilhot,Jörge E. Cortes,Stephen G. O’Brien,Tillmann Krahnke,Richard A. Larson	2007	8
17	Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. Blood ·Hagop M. Kantarjian,Charles L. Sawyers,Andreas Hochhaus,Charles A. Schiffer,François Guilhot,Dietger Niederwieser,Carlo Gambacorti,Richard M. Stone,Thomas Fischer,John M. Goldman,Tillmann Krahnke,Manisha Mone,Moshe Talpaz,Brian Druker	2006	4
18	The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients Clinical Endocrinology ·Joost van der Hoek,Aart‐Jan van der Lelij,Richard A. Feelders,Wouter W. de Herder,André G. Uitterlinden,Kwai W. Poon,Viktor Boerlin,Ian Lewis,Tillmann Krahnke,Leo J. Hofland,Steven W. J. Lamberts	2005	46
19	Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. Blood ·Carlo Gambacorti,Moshe Talpaz,Charles L. Sawyers,Brian Druker,Andreas Hochhaus,Charles A. Schiffer,François Guilhot,Dietger Niederwieser,Richard M. Stone,John M. Goldman,Manisha Mone,Tillmann Krahnke,Insa Gathmann,Hagop M. Kantarjian	2005	13
20	A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients The Journal of Clinical Endocrinology & Metabolism ·Joost van der Hoek,Wouter W. de Herder,Richard A. Feelders,Aart‐Jan van der Lely,André G. Uitterlinden,Viktor Boerlin,Christian Bruns,Kwai W. Poon,Ian Lewis,Gisbert Weckbecker,Tillmann Krahnke,Leo J. Hofland,Steven W. J. Lamberts	2004	117

About Tillmann Krahnke

Tillmann Krahnke is a scholar working on Hematology, Genetics and Rheumatology, having authored 27 papers that have together received 1.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers), Eosinophilic Disorders and Syndromes (7 papers), Cholinesterase and Neurodegenerative Diseases (5 papers), Dementia and Cognitive Impairment Research (4 papers), Alzheimer's disease research and treatments (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and COVID-19 Clinical Research Studies (2 papers). The work is most often cited by research in Hematology (1.1k citations), Genetics (925 citations) and Rheumatology (683 citations). Tillmann Krahnke has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Brian Druker, François Guilhot, Richard A. Larson, Stephen G. O’Brien, Insa Gathmann, Yanfeng Wang, Jörge E. Cortes, Hagop M. Kantarjian, Marc S. Rudoltz and Manisha Mone. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact